Pulmonary delivery of nucleic acids.
The lung is an appropriate present and future target for gene therapy approaches designed to treat inherited monogenic diseases, eradicate bronchial tumours, transfer pharmacologically active products to the general circulation, express enzymes to catabolise toxins, manage pulmonary hypertension and lung injury and vaccinate against infection. Despite 35 years of gene therapy research and some significant milestones in molecular biology, the clinical potential of gene therapy has yet to be realised. In pulmonary gene therapy the nucleic acid cargo needs to be delivered to cells in the target region of the lung, and even in cases when these targets are well defined this is severely limited by the pulmonary architecture, clearance mechanisms, immune activation, the presence of respiratory mucus and the availability of a truly representative biological model. The challenge from a drug delivery perspective is to consider the suitability of conventional nebulisers and inhalers for delivering DNA to the lung and design and apply integrated formulation and device solutions specific to nucleic acid delivery.
Birchall
James
J
D000280:Administration, Inhalation; D000336:Aerosols; D003550:Cystic Fibrosis / Q000628:therapy; D015316:Genetic Therapy / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy; D009330:Nebulizers and Vaporizers; D009696:Nucleic Acids / Q000008:administration & dosage* / Q000235:genetics; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D019444:Vaccines, DNA / Q000008:administration & dosage; D019896:alpha 1-Antitrypsin Deficiency / Q000628:therapy
D000336:Aerosols; D009696:Nucleic Acids; D034741:RNA, Small Interfering; D019444:Vaccines, DNA